No Clinical Benefit of LY-CoV555 Antibodies Plus Remdesivir in Hospitalized COVID-19 Patients

How to Cite

OrthoEvidence. No Clinical Benefit of LY-CoV555 Antibodies Plus Remdesivir in Hospitalized COVID-19 Patients. ACE Report. 2021;20(1):4. Available from: https://myorthoevidence.com/AceReport/Report/13409

Study Type:Therapy

OE Level Evidence:1

Journal Level of Evidence:1

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

N Engl J Med. 2021 Mar 11;384(10): 905-914.

Contributing Authors: Group ACTIV-3/TICO LY-CoV555 Study JD Lundgren B Grund CE Barkauskas TL Holland RL Gottlieb U Sandkovsky SM Brown KU Knowlton WH Self DC Files MK Jain T Benfield ME Bowdish BG Leshnower JV Baker JU Jensen EM Gardner AA Ginde ES Harris IS Johansen N Markowitz MA Matthay L √òstergaard CC Chang VJ Davey A Goodman ES Higgs DD Murray TA Murray R Paredes MKB Parmar AN Phillips C Reilly S Sharma RL Dewar M Teitelbaum D Wentworth H Cao P Klekotka AG Babiker AC Gelijns VL Kan MN Polizzotto BT Thompson HC Lane JD Neaton

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Three hundred and fourteen hospitalized patients with COVID-19 were randomized to receive a single intravenous infusion of LY-CoV555 antibody therapy (n=163) or placebo (n=151) for the improvement of recovery and reduction of adverse events. The primary outcomes of interest was sustained recovery (discharged home and remaining at home for at lest 14 days) and a composite safety outcome of death, s...